Ultragenyx Pharmaceutical | RARE - Cash And Equivalent


Ultragenyx Pharmaceutical reported $166.11M in Cash and Equivalent for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.31B
Cash and Equivalent USD 166.11M
Cost of Sales USD 23M
Current Assets USD 719.79M
Current Liabilities USD 293.24M
Debt USD 36.3M
EBIT USD -193.57M
EBITDA USD -91.34M
Employees 1.29K
EPS Earnings Per Share USD -1.17
Equity Capital and Reserves USD 151.29M
Gross Profit on Sales USD 143.49M
Interest Expense on Debt USD 14.04M
Interest Income USD 5.79M
Loan Capital USD 782.75M
Market Capitalization USD 2.61B
Net Income USD -114.95M
Operating Expenses USD 274.38M
Operating Profit USD -193.57M
Ordinary Share Capital USD 96.35M
Pre-Tax Profit USD -114M
Sales Revenues USD 166.5M
Selling and Administration Expenses USD 86.65M
Stock USD 46.5M
Trade Creditors USD 34.24M
Trade Debtors USD 124.46M

Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
Agios Pharmaceuticals USD 80.87M 1.91M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Insmed USD 1.28B 881.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Kyowa Hakko Kirin JPY 214.37B 30.31B Mar/2025
MacroGenics USD 130.69M 52.15M Jun/2025
Moderna USD 1.28B 344M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025